Minjun Chen received his Ph.D. degree from Zhejiang University, China, in 2003. Starting in 2003, he worked as an Assistant Professor at the School of Pharmacy at Shanghai Jiao Tong University in China and was promoted to Associate Professor in 2005. In 2006, he came to the National Center for Toxicological Research (NCTR) as a Postdoctoral Fellow jointly with the University of Medicine and Dentistry of New Jersey. He was promoted to an FDA staff fellow in the division in 2008 and currently is a staff fellow in the division. He received the FDA Award for “Outstanding Junior Investigator” in 2012, the NCTR “Scientific Achievement Award” in 2014, and the FDA “Scientific Achievement Award for Excellence in Analytical Science” in 2017. He established and currently co-chairs the FDA Liver Toxicity Working Group (LTWG), which is officially endorsed by the Office of the Chief Scientist with 60 FDA scientists involved to gather the expertise of drug-induced liver injury (DILI) within the FDA. His primary research interests encompass bioinformatics, drug safety, biomarker discovery, and toxicogenomics.